| Name | Title | Contact Details |
|---|
A family-owned, integrated agri-business with cattle, citrus, farming, forestry, hunting and land and water resource management.
Liverpool Football Club was founded in 1892 and is one of the worlds most historic and famous football clubs. Honours include 19 League Titles, eight FA Cups, ten League Cups, six European Cups, three UEFA Cups, four European Super Cups, 16 Charity Shields, one FIFA Club World Cup, two Womens Super League and one Womens Championship. As a socially responsible club, Liverpool FC is proud of its heritage and plays a proactive role in its communities through its official charity, Liverpool FC Foundation, which helps children and families in Merseyside and beyond, and the Red Neighbours programme, which creates events and experiences specifically aimed at improving the lives of those living in and around the Anfield area (L4, L5 and L6). Liverpool FC is a global brand and works with leading edge commercial partners around the world providing unparalleled commercial opportunities.
Jordan & Skala Engineers is a leading consulting-engineering firm that specializes in mechanical, electrical, and plumbing (MEP) engineering services. Founded in 1953 and headquartered in Norcross, GA, the company operates multiple regional design offices across the United States, allowing it to effectively meet the diverse needs of its clients. With a workforce of approximately 310 employees, Jordan & Skala Engineers is licensed to operate in all 50 states. The firm offers a wide range of services, including MEP engineering, structured cabling for communications, security system design, audio-visual solutions, and comprehensive energy services aimed at promoting sustainability. Additionally, the company conducts facility assessments to optimize existing buildings. Jordan & Skala Engineers is committed to engineering excellence, focusing on quality, safety, and strong client relationships through teamwork and innovative designs. The company has been recognized as a Top U.S. Workplace in 2023, underscoring its dedication to employee satisfaction and industry leadership.
The Ken Ganley Automotive Group is the fastest growing dealership group in Northeast Ohio and beyond! We currently rank #1 in Ohio and #14 in the country. Our group is a collection of best-in-class dealerships that offer a wide array of quality new and used car models in convenient locations. At the Ken Ganley Auto Group, we believe that our people are our most important assets, along with our culture of leadership, integrity, customer focus and teamwork. Our people are the foundation of our brand, and our success is dependent on preserving our reputation of respect and quality. We are a company that believes in our core values and upholding them through great people, high standards and best practices. The core values of our organization are what shape every action we take and every decision that is made. We are defined by our integrity. We believe in doing what is right for our fellow team members, our customers and our corporate partners. We are responsive, professional, and handle every experience honestly and with class. Together, we have created an image that has resulted in a positive public perception. The image of a leader. Our customers are our #1 priority. We treat them like family, working hard to exceed their expectations. We are committed to continuing our tradition of success, performance and quality customer service. Our team members are entrusted to make sure each and every customer feels valued and listened to. When a customer enters our dealerships, they know they will have a dependable, quality experience every time. Thanks for visiting our page and well see you soon in the showrooms!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.